InvestSMART

Racura Oncology Ltd (ASX:RAC)

ALERT: Price-sensitive ASX Announcement for RAC
Current share price for RAC : $2.250 -0.07 (-3.02%)+
Announcement
Release
16 Jun 2026 12:36PM
Price at Release
$2.320
Full Release
download
Summary
Racura Oncology Ltd has successfully raised $34.3 million from both Bonus and Piggyback Option conversions and private placements to advance its clinical programs targeting acute myeloid leukaemia (AML), mutant epidermal growth factor receptor non-small cell lung cancer, and anthracycline cardioprotection in solid tumour patients. The company emphasizes its shareholders' confidence and has not incurred any broker or underwriter fees during these fundraising activities. Racura's lead compound, (E,E)-bisantrene, demonstrates a promising safety profile and effort is ongoing to enhance its intellectual property coverage internationally. Collaborations with various academic and health institutions support Racura's mission to improve cancer treatments globally, with strategic partnerships and licensing agreements being actively pursued to facilitate global access to its proprietary formulation, RC220.
Key Points
  • Racura Oncology Ltd raised $34.3 million to fund oncology trials.
  • Funds were raised through Bonus and Piggyback Option conversions and private placements.
  • The capital will be used for trials in Acute Myeloid Leukaemia (AML) and EGFRm non-small cell lung cancer.
  • No broker or underwriter fees were paid in connection with the fundraising.
  • Racura's lead asset is (E,E)-bisantrene, targeting cancer growth regulator MYC.
  • Racura is collaborating with several universities and health institutions.
  • The company is exploring partnerships for broader access to RC220 globally.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.